ergoline and Hypertension--Pulmonary

ergoline has been researched along with Hypertension--Pulmonary* in 2 studies

Other Studies

2 other study(ies) available for ergoline and Hypertension--Pulmonary

ArticleYear
[Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline].
    Archivos de bronconeumologia, 2009, Volume: 45, Issue:2

    Cabergoline is a synthetic dopamine agonist used to treat Parkinson disease. The drug occasionally induces pleuropulmonary adverse effects, which manifest as pleural thickening or effusion, interstitial pneumonitis, pulmonary infiltrates, or fibrosis. We report a rare case of pleural effusion and severe pulmonary hypertension in a 79-year-old man with Parkinson disease who had been treated with cabergoline for 1 year. The symptoms disappeared 10 months after the drug was discontinued.

    Topics: Aged; Antiparkinson Agents; Cabergoline; Ergolines; Humans; Hypertension, Pulmonary; Male; Parkinson Disease; Pleural Effusion

2009
[Changes induced by a new ergoline-like vasoactive substance on various parameters of the systemic and pulmonary circulation and on pneumoscintigraphic recording].
    La Clinica terapeutica, 1972, Oct-31, Volume: 63, Issue:2

    Topics: Adult; Blood Pressure; Bromine; Ergolines; Humans; Hypertension, Pulmonary; Middle Aged; Nicotinic Acids; Oxygen Consumption; Pulmonary Circulation; Pulmonary Heart Disease; Radionuclide Imaging; Respiratory Function Tests

1972
chemdatabank.com